A phase 1 study of 4’-thio-2’-deoxycytidine in patients with solid tumors
Cancer Chemotherapy and Pharmacology · 05.11.2026 · 96 (1)
DOI: 10.1007/s00280-026-04969-8 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 05.11.2026. Verfasst von Geraldine O'Sullivan Coyne und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Deoxycytidine, Neoplasms, Thionucleosides. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Purpose
The DNA methyltransferase (DNMT) inhibitor 4’-thio-2’-deoxycytidine (TdCyd), a second-generation cytidine analog, demonstrated potent preclinical antitumor activity and favorable pharmacokinetics, which led us to explore its safety, efficacy and anti-tumor activity in patients with solid tumors.
Methods
Adult patients with advanced solid tumors received TdCyd orally on days 1–5 and 8–12 in 21-day cycles. Dose escalation proceeded according to design 4 of the Simon accelerated titration design, changing to a 3 + 3 dose escalation design in the event of dose-limiting toxicities. Blood samples were collected for circulating tumor cell (CTC) evaluation of p16 re-expression as a marker of TdCyd epigenetic modulation, and for pharmacokinetic analysis.
Results
Twenty-seven patients were enrolled. The maximum tolerated dose was not reached. The best response was prolonged stable disease (SD), with 3 patients on treatment for ≥ 6 cycles, and there was no dose-response relationship. An increase in the proportion of p16-expressing cytokeratin-positive (CK+) CTCs was detected in 71% (15 of 21) of patients evaluable for p16 response at every dose level in which patients were assessable for pharmacodynamic response; p16 re-expression in vimentin-positive CTCs was reported in 38% (6 of 16) of evaluable patients. Plasma levels of TdCyd metabolites were largely dose proportional and higher levels were detected in patients with higher incidence and severity of study drug–related adverse events.
Conclusion
Prolonged SD and p16 re-expression at lower TdCyd dose levels suggest that longer exposures to low concentrations is worth exploring in future trials, including studies of TdCyd in therapeutic combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, 20892, MD, USA.
- START Center for Cancer Research, Northwell Health Cancer Institute, NY, USA.
- Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
- Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
- Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
- Clinical Monitoring Research Program, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Förderung
- National Cancer Institute
Zitieren
APA
O'Sullivan Coyne, G., Kummar, S., Rubinstein, L., Anderson, L., Hill, K., Bruns, A., Moore, N., Ferry-Galow, K. V., Miller, B., Wang, L., Covey, J. M., Piekarz, R. L., Kuhlmann, L., Miller, S. B., Juwara, L., Collins, J., Kinders, R. J., Parchment, R. E., Chen, A. P., & Doroshow, J. H. (2026). A phase 1 study of 4’-thio-2’-deoxycytidine in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04969-8
Vancouver
O'Sullivan Coyne G, Kummar S, Rubinstein L, Anderson L, Hill K, Bruns A, et al. A phase 1 study of 4’-thio-2’-deoxycytidine in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04969-8
BibTeX
@article{OSullivanCoyne2026,
author = {O'Sullivan Coyne, Geraldine and Kummar, Shivaani and Rubinstein, Larry and Anderson, Larry and Hill, Kimberly and Bruns, Ashley and Moore, Nancy and Ferry-Galow, Katherine V and Miller, Brandon and Wang, Lihua and Covey, Joseph M and Piekarz, Richard L and Kuhlmann, Laura and Miller, Sarah B and Juwara, Lamin and Collins, Jerry and Kinders, Robert J and Parchment, Ralph E and Chen, Alice P and Doroshow, James H},
title = {A phase 1 study of 4’-thio-2’-deoxycytidine in patients with solid tumors},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04969-8}
}
EUVIMED